Home › Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
 

Keywords :   


Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes

2013-03-28 09:57:29| dairynetwork News Articles

Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.

Tags: the of treatment trial

Category:Agriculture and Forestry

Latest from this category

All news
28.06Cattle producers celebrate Supreme Court decision to rein in administrative overreach
28.06Commitment leads to success in cattle marketing
28.06Cost of summer cookout reaches record high
28.06Farm Progress America, June 28, 2024
28.06Farm Progress America, June 28, 2024
28.06USDA moves to change livestock competition rules
28.06Learning to listen to nursery pigs
27.06Texas & Southwestern Cattle Raisers Association concludes 2024 summer meeting
Agriculture and Forestry »
29.06Tropical Storm Beryl Public Advisory Number 3A
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Graphics
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Weekly Recap: PPG, Hempel, Beckers Group Top This Weeks Stories
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 3
More »